2025 Partners

Lead Partner

Natera

Natera™ has developed one of the largest known clinicogenomic database for renal disease. This database is built with matched data from 40,000 patients who have received the Renasight™ test, a 385-gene panel for patients with kidney disease. Natera’s™ database enables drug developers to accelerate pre-clinical target discovery, enroll clinical trials faster, and maximize budgets for approved targeted therapies.

www.natera.com/organ-health

Expertise Partners

SeaStar Medical

SeaStar Medical is a medical technology company that is redefining how extracorporeal therapies may reduce the consequences of a dysregulated immune response on vital organs. SeaStar Medical’s novel selective cytopheretic device (SCD) is designed to provide a potentially life-saving solution to critically ill patients. The SCD is a cell-directed extracorporeal therapy that targets the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. Promising data from multiple studies show that the SCD has the potential to improve clinical outcomes including overall survival and dialysis independence in acute kidney injury.

www.seastarmedical.com

MediBeacon

MediBeacon is a medical technology company specializing in advances of fluorescent tracer agents and transdermal measurement with a focus on developing actionable point of care organ function measurements. MediBeacon technology is being shown to have many preclinical nephrology applications with over 400 peer reviewed publications and conference abstracts in which Transdermal GFR (tGFR) has been used. In 2018 the U.S. Food and Drug Administration granted Breakthrough Device designation to the Transdermal GFR Measurement System (TGFR). Clinical studies in subjects with normal and impaired kidney function are ongoing.

www.medibeacon.com

Antaros Medical

Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies. Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have helped our customers to solve complex problems to empower confident decision-making at every stage of clinical drug development, from small mechanistic studies to large scale studies. Disease areas: CV, renal & metabolic diseases and oncology.

www.antarosmedical.com

Program Partners

FibroFind

FibroFind specialises in the application of advanced technologies for interrogating human disease. Leveraging our expertise, we have developed proprietary bioreactor-cultured precision-cut tissue slices (PCTS) that demonstrate exceptional performance in biomarker identification, toxicology, target discovery and drug efficacy evaluation. By harnessing robotics, AI-guided data analysis and a highly skilled team, FibroFind ensures unparalleled quality in all studies. Our portfolio includes PCTS from kidney, liver, lung, heart and skin, in 12, 24 and 96 well formats, allowing us to customise studies to meet your specific needs and deliver results that drive your research forward.

www.fibrofind.com

Industry Partners

ENYO Pharma

Industry Partner

ENYO Pharma (Lyon, France) is a clinical-stage biopharmaceutical company. The company is developing a portfolio of drug candidates to improve quality of life and avoid end stage renal disease and dialysis for patients with rare and common kidney diseases. Its lead candidate Vonafexor, as well as fast follower EYP651, is a once-daily oral treatment. Both compounds have fibrolytic and anti-inflammatory properties that are broadly applicable across several renal diseases. ENYO Pharma is currently starting its Phase 2 ALPESTRIA-1 study to confirm Vonafexor’s effect on renal function (eGFR) in Alport Syndrome, as was seen in its Phase 2 LIVIFY study of patients with both kidney impairment and fibrotic liver disease. ENYO Pharma is also preparing additional Phase 2 trials to extend its franchise to other renal diseases.

www.enyopharma.com

Innovation Partners

Exagen

Exagen Inc. is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring.

www.exagen.com

Nephrix Biosolutions

NEPHRIX Biosolutions is the only CRO dedicated exclusively to preclinical renal research. We offer a full range of in vitro and in vivo services to support every aspect of kidney research. Our expert team delivers high-quality studies that assist pharmaceutical and biotech companies in developing innovative treatments. With validated models and deep expertise in renal biology, we are committed to providing precise, reliable data to accelerate the path from discovery to therapeutic solutions.

www.nephrix-biosolutions.com

Exhibition Partners

Perspectum

Pioneering precision healthcare, Perspectum is leading innovation in non-invasive technology. The company’s track record speaks volumes, having delivered innovative imaging, operational excellence, and protocol consultation services in over 80 commercial trials spanning Phase 0-III in a range of chronic diseases. With a focus on kidney health, our quantitative MRI biomarker suite offers a comprehensive assessment of structural and functional metrics, enabling efficient patient screening and therapeutic efficacy assessment. Experience the future of kidney care with Perspectum’s groundbreaking solutions.

www.perspectum.com

National Jewish Health

National Jewish Health Advanced Diagnostic Laboratories has more than 30 years of experience performing complement testing. Our complement laboratory has the most comprehensive test menu in the industry for pre-clinical and clinical trials, as well as in vitro testing. Our scientists have extensive experience performing and designing complement activation tests, with more than 1,000 successful studies completed in our laboratory. Join us at our booth to discuss our new urine matrix testing for complement activation.

www.nationaljewish.org/for-professionals/diagnostic-testing/adx/overview

George Clinical

George Clinical is a leading global clinical research organization founded in Asia- Pacific driven by scientific expertise and operational excellence. George Clinical is known as the industry-leading CRO for our innovative leadership in the kidney space. With more than 20 years of experience and 500 people managing 39 geographical locations throughout the USA, Asia-Pacific region, and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration, and post-marketing trials.

www.georgeclinical.com

Event Partners

Physiogenex

Event Partner

Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH, dyslipidemia, inflammation, diabetic nephropathy, HFpEF and atherosclerosis.

For >20 years, we have been evaluating the efficacy of our clients' drugs using gold-standard experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners.

Our expertise – your success.

www.physiogenex.com

Become a Partner

Ellie Bilko
Partnership Director
Hanson Wade
sponsor@hansonwade.com

PARTNER

2025 Partners

Natera

SeaStar Medical

MediBeacon

Antaros Medical

FibroFind

ENYO Pharma

Exagen

Nephrix Biosolutions

Perspectum

National Jewish Health

George Clinical

Physiogenex

Become a Partner

VENUE

LOCATION

OUR CONTACT DETAILS

JOIN OUR TEAM

ABOUT US

EXPLORE OUR PRODUCTS

SEARCH